Sai Parenteral’s IPO – CAPEX plan for Scale and Value Chain Advantages

This IPO News guide/article covers “Sai Parenteral's IPO – CAPEX plan for Scale and Value Chain Advantages”. The page is organized around key highlights, sai parenteral ipo, zerodha trade@20, compare stock brokers side-by-side. IPO News presents the structured facts and tables in its own layout and wording.

Topics Covered

• Key highlights
• Sai Parenteral IPO
• Zerodha Trade@20
• Compare Stock Brokers Side-by-Side

Key Facts

• India's trusted financial research platform since 2015. Live IPO GMP, subscription data, allotment status, Rights Issues, NCDs and unbiased stock broker reviews.
• ₹111 crore capex towards capacity expansion and EU-GMP upgrades
• ₹18 crore investment in R&D to strengthen development capabilities
• IPO size of ₹408.79 crore including ₹285 crore fresh issue and ₹123.79 crore in OFS
• Fig.1 – Oral Solid Dosage Facility in Bhongir, Telangana
• Fig.2 – Under Construction facility in Adelaide Australia
• SAI Parenteral’s ₹409 crore IPO is open from March 24 to March 27. The issue size is ₹408.79 crore including ₹285 crore fresh issue and ₹123.79 crore in OFS from non-promoter shareholders.
• Issue opens Mar 24, 2026 | Closes Mar 27, 2026 | Listing expected Apr 2, 2026
• Want to start your investment journey? Join India's Pioneer Discount Broker – ZERODHA – Free Delivery Trade, Maximum Rs 20 for F&O and Intraday, Free Direct Mutual Fund investment.
• Why NSE IPO Is One Of India's Most Awaited Listings
• DilMil Partners with Open Atlas Summit 2025 for Immigrant Dating Lounge
• ETT Limited Wins ₹60 Cr Deal, Experts Eye Multibagger Potential at ₹14

Source record: View original public source ↗